- Home
- VTYX vs EDIT Comparison
VTYX vs EDIT Comparison
Compare VTYX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- EDIT
- Stock Information
- Founded
- VTYX 2018
- EDIT 2013
- Country
- VTYX United States
- EDIT United States
- Employees
- VTYX N/A
- EDIT N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTYX Health Care
- EDIT Health Care
- Exchange
- VTYX Nasdaq
- EDIT Nasdaq
- Market Cap
- VTYX 154.9M
- EDIT 156.5M
- IPO Year
- VTYX 2021
- EDIT 2016
- Fundamental
- Price
- VTYX $2.26
- EDIT $2.25
- Analyst Decision
- VTYX Buy
- EDIT Buy
- Analyst Count
- VTYX 4
- EDIT 13
- Target Price
- VTYX $11.33
- EDIT $6.73
- AVG Volume (30 Days)
- VTYX 2.3M
- EDIT 2.4M
- Earning Date
- VTYX 08-07-2025
- EDIT 08-06-2025
- Dividend Yield
- VTYX N/A
- EDIT N/A
- EPS Growth
- VTYX N/A
- EDIT N/A
- EPS
- VTYX N/A
- EDIT N/A
- Revenue
- VTYX N/A
- EDIT $35,837,000.00
- Revenue This Year
- VTYX N/A
- EDIT N/A
- Revenue Next Year
- VTYX N/A
- EDIT N/A
- P/E Ratio
- VTYX N/A
- EDIT N/A
- Revenue Growth
- VTYX N/A
- EDIT N/A
- 52 Week Low
- VTYX $0.78
- EDIT $0.91
- 52 Week High
- VTYX $3.39
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- VTYX 56.94
- EDIT 63.76
- Support Level
- VTYX $2.10
- EDIT $2.05
- Resistance Level
- VTYX $2.42
- EDIT $2.55
- Average True Range (ATR)
- VTYX 0.22
- EDIT 0.23
- MACD
- VTYX -0.02
- EDIT 0.03
- Stochastic Oscillator
- VTYX 53.99
- EDIT 66.29
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.